Saturday 17 October 2026
Export KAPA’s income statement to Excel — free account
Kairos Pharma, Ltd.
KAPA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 25.0% and free cash flow fell 25.7%, each against the same quarter a year earlier.
0.60
0.07
−10.45%
Follow KAPA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 8.54 | 2.80 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 28.00 | 22.75 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 3 | 4 | 4 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | (1) | (2) | (3) | (5) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (1) | (2) | (3) | (5) | |||||
| Depreciation | — | — | — | — | — | — | 1 | 0 | 0 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (0.68) | (1.22) | (1.61) | (2.10) | |||||
| Cash flow | — | — | — | — | — | — | (0.23) | 0.05 | (2.44) | (1.31) | |||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | (0.23) | 0.05 | (2.44) | (1.31) | |||||
| Book value | — | — | — | — | — | — | (0.76) | (1.40) | 2.94 | 2.41 | |||||
| Shares, m | — | — | — | — | — | — | 2 | 1 | 2 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | 0 | 0 | (4) | (3) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | 0 | 0 | (4) | (3) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (1) | (2) | 3 | 5 | ||||
| Total debt | — | — | — | — | — | — | 1 | 1 | — | — | |||||
| Net debt | — | — | — | — | — | — | 0 | 1 | (4) | (5) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (1) | (2) | 5 | 6 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (181.11) | (77.32) | (88.51) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | (227.03) | (346.52) | |||||
| ROE | — | — | — | — | — | — | 0.00 | 111.27 | (192.96) | (97.99) | |||||
Negative figures in brackets.
Charts ten years each
Kairos Pharma, Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ELAB PMGC Holdings Inc. | $2.5M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | Compare |
| NTBLQ Notable Labs, Ltd. | $2.4M | — (loss-making) | — (loss-making) | −96.88% (below 0%: shrinking) | n/m | −26.63% (below 0%: shrinking) | 100.00% | (269,000.00%) | Compare |
| VBIO Valion Bio, Inc. | $2.4M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $2.4M | — (loss-making) | — (loss-making) | +365,433.33% (above 0%: growing) | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BPTSY Biophytis SA Sponsored ADR | $2.4M | — (loss-making) | — | — | n/m | +53.15% (above 0%: growing) | 0.00% | — | Compare |
| WINT Windtree Therapeutics, Inc. | $2.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +1.12% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KAPA Kairos Pharma, Ltd. | $2.3M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | |
| VRAX Virax Biolabs Group Limited | $2.2M | — (loss-making) | — (loss-making) | — | −855.56% (below 0%: shrinking) | +32.24% (above 0%: growing) | (53.57%) | 0.00% | Compare |
| CLSDQ Clearside Biomedical, Inc. | $2.2M | — (loss-making) | — (loss-making) | −80.64% (below 0%: shrinking) | n/m | +8.15% (above 0%: growing) | 100.00% | (3,502.49%) | Compare |
| Median of peers | $2.4M | — | — | −32.38% | — | +4.64% | 0.00% | 0.00% |
Kairos Pharma, Ltd. (KAPA) key facts
- Concern: Kairos Pharma, Ltd. reported a net loss of $5.4 million, or a loss of $2.10 per share, for fiscal 2025.
- Kairos Pharma, Ltd. (KAPA) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, KAPA traded at $0.60, a market capitalization of $2.3 million.
- Return on equity was −98.0% and debt-to-equity 0.00.